Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
AstraZeneca
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
63High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07611110CT.gov AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01) | — | Recruiting | — | — | — |
NCT06832774CT.gov Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients | — | Recruiting | — | — | — |
NCT07086651CT.gov A Study to Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC) | — | Completed | — | — | — |
NCT07002320CT.gov Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer | — | Recruiting | — | — | — |
NCT06992232CT.gov Radiotherapy or Surgery Combined With Intense Androgen Deprivation Therapy for mCRPC | — | Recruiting | — | — | — |
NCT06320067CT.gov A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer | — | Recruiting | — | — | — |
NCT06430411CT.gov Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study | — | Not Yet Recruiting | — | — | — |
NCT06972511CT.gov Maximal Tumor Eradication for Oligometastatic Prostate Cancer | — | Recruiting | — | — | — |
NCT05717582CT.gov Maximal Cytoreductive Therapies on Post-treatment Metastases in Pts With mHSPC During Apalutamide Plus ADT Treatment | — | Not Yet Recruiting | — | — | — |
NCT05649943CT.gov Multimodal Approach in Patients With mHSPC. Randomized Trial of APA+ADT vs APA-ADT and Local Treatment | — | Recruiting | — | — | — |
Show 16 more trialsShow fewer
NCT05751941CT.gov Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer | — | Recruiting | — | — | — |
NCT05701007CT.gov Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland | — | Completed | — | — | — |
NCT05683964CT.gov Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression | — | Active Not Recruiting | — | — | — |
NCT05367440CT.gov Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT05413421CT.gov Study of ORIC-944 in Patients With Metastatic Prostate Cancer | — | Recruiting | — | — | — |
NCT04662580CT.gov ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT04666129CT.gov Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer | — | Completed | — | — | — |
NCT04585932CT.gov Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study | — | Withdrawn | — | — | — |
NCT04601441CT.gov Study to Evaluate ctDNA of mCSPC Patients Receiving Apalutamide in Japan | — | Unknown | — | — | — |
NCT04423211CT.gov Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging | — | Recruiting | — | — | — |
NCT04267887CT.gov Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT03821792CT.gov Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT03903835CT.gov ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | — | Recruiting | — | — | — |
NCT02913196CT.gov Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC | — | Completed | — | — | — |
NCT02703623CT.gov Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT02123758CT.gov A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metastatic Prostate Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Apalutamide (this asset) | AstraZeneca | Approved | BB · 67 |
| AXUMIN | VA Greater Los Angeles Healthcare System | P4 | BBB |
| Leuporelin | Mayo Clinic | P4 | BBB |
| Abiraterone | Mayo Clinic | P4 | BB |
| Prednisone | Mayo Clinic | P4 | BB |
| Pembrolizumab | CuraCell TX AB | P2 | BB |
| Sipuleucel-T | Yale University | P2 | BB |
| Cabazitaxel | AstraZeneca | P4 | BB |
| Degarelix | Praful Ravi, MB BCHir, MRCP | P3 | BB |
+42 more in the Metastatic Prostate Carcinoma cohort
Other indications for Apalutamide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prostate Neoplasm | — | P4 | BB · 67 |
| Prostate Carcinoma | — | P3 | BB · 64 |
| Castration-Resistant Prostate Carcinoma | — | P3 | B · 62 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Apalutamide in Metastatic Prostate Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/apalutamide-metastatic-prostate-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →